恢复期血浆治疗住院COVID-19患者的随机临床试验:PERUCONPLASMA研究方案结构化摘要
PERUCONPLASMA是一项在秘鲁利马三家公立医院进行的IIb期开放标签、随机、优效性临床试验,按1:1分配住院的重症或危重症COVID-19患者,比较恢复期血浆联合局部标准治疗与单纯局部标准治疗的安全性和有效性。主要目标是评估30天全因住院死亡率是否降低,计划入组100例患者。
要点
- 恢复期血浆供体为30-60岁男性,既往3个月内诊断为重症COVID-19肺炎且症状缓解至少28天。
- 主要安全性结局为血浆输注后24小时内相关严重不良反应发生率。
- 主要疗效结局为随机化后30天内全因住院死亡率。
核心结论
- 该研究旨在验证重症COVID-19康复者恢复期血浆治疗住院COVID-19患者的安全性和降低30天全因住院死亡率的有效性。
研究设计与样本
- PERUCONPLASMA为IIb期开放标签、随机、优效性临床试验,1:1分配,在秘鲁利马三家三级公立医院的实际临床实践中进行。
- 计划入组100例实验室确诊的SARS-CoV-2感染住院患者,随机分配至恢复期血浆联合局部标准治疗组或单纯局部标准治疗组,随访30天或至出院。
- 随机化通过电子病例报告表以区组大小2、4、6进行,使用Stata v.16.0的ralloc程序,对参与者与研究 staff 非盲,但统计分析采用盲法。
关键数值与推荐
- 纳入标准:年龄≥18岁;实验室确诊COVID-19住院;重症(呼吸频率≥22次/分、氧饱和度≤93%、血气异常如PaO2<60 mmHg、PaCO2>50 mmHg或Pa/FiO2<300中至少2项)或危重症(机械通气需求<72小时或休克);能提供知情同意;有ABO血型相容的恢复期血浆单位。
- 排除标准包括:输血禁忌(如既往过敏反应、充血性心力衰竭)、血流动力学不稳定(对血管升压药无反应的PA<60 mmHg)、未控制的合并感染、木僵或昏迷、血小板<50,000/μL或弥散性血管内凝血、血清肌酐>3.5 mg/dL或需透析、总胆红素>6 mg/dL或不明原因黄疸、心肌梗死或急性冠脉综合征、活动性或近期(<7天)颅内出血、妊娠。
- 干预:实验组接受1至2单位200至250 ml恢复期血浆联合局部标准治疗,对照组仅接受局部标准治疗;血浆输注后6小时和24小时评估输血事件,所有参与者在入组后第3、7、30天评估。
- 主要安全性结局:血浆输注后24小时内相关严重不良反应发生率;主要疗效结局:随机化后30天内全因住院死亡率;次要疗效结局包括住院时间、ICU停留时间、机械通气需求等。
- 样本量:使用Fleiss公式带连续性校正,检测两组死亡率从50%降至20%,置信水平95%、把握度80%,每组需45例,调整10%脱落率后每组50例,共100例。
临床怎么用
- 对于住院的重症或危重症COVID-19患者,在标准治疗基础上加用恢复期血浆可能降低30天全因住院死亡率,但需等待试验结果确认。
- 供体选择既往重症COVID-19肺炎康复者,旨在最大化获取高滴度中和抗体血浆的概率,因秘鲁常规无法检测中和抗体滴度。
- 治疗过程中需在血浆输注后24小时内密切监测严重不良反应,并在第3、7、30天评估疗效指标。
局限性
- 开放标签设计,参与者和研究 staff 知晓分组,可能引入偏倚;但统计分析采用盲法。
- 样本量较小(100例),可能限制对次要结局和亚组分析的统计效能。
- 供体血浆中和抗体滴度未常规检测,仅储存样本供未来定量,可能影响治疗效果的异质性。
- 试验在秘鲁利马的三家医院进行,结果外推需谨慎。
- 试验方案版本5.0(2021年1月4日),招募预计2021年3月底结束,当前结果尚未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The general objective of this study is to test the hypothesis that administration of convalescent plasma from donors with previous diagnosis of severe COVID-19 pneumonia is safe and associated with a decrease in all-cause in-hospital mortality among hospitalized patients with COVID-19 at 30 days in comparison with standard treatment alone. The secondary objectives are as follows: (1) to assess the efficacy of convalescent plasma to reduce the length of hospitalization, (2) to assess the efficacy of convalescent plasma to reduce the length of ICU stay, and (3) to assess the efficacy of convalescent plasma on reducing the requirement of invasive mechanical ventilation or ICU stay. TRIAL DESIGN: PERUCONPLASMA is a IIb phase open label, randomized, superiority clinical trial with 1:1 allocation taking place in real life routine clinical practice at public hospitals in Lima, Peru. Participants will be randomized to receive convalescent plasma along with local standard treatment or local standard treatment alone. After allocation, all participants will be followed for a total of 30 days or until hospital discharge, whichever occurs first. PARTICIPANTS: The population for the study are patients with severe disease with a confirmed laboratory test for SARS-CoV-2 infection hospitalized in 3 tertiary-care hospitals in Lima, Peru. Subjects are eligible for the trial if they meet all of the following inclusion criteria: 1. Age 18 or older 2. Hospitalization due to COVID-19 with laboratory confirmation (either with serologic, molecular, or antigen test along with a compatible clinical presentation) 3. Severe or critical COVID-19 disease Severe illness was defined by 2 or more of the following: Respiratory rate of 22 or more Hypoxemia with oxygen saturation equal or less than 93% Abnormal blood gas analysis (PaO2 < 60 mmHg, PaCO2 > 50 mmHg, or Pa/FiO2 < 300) Critical disease was defined by either: Mechanical ventilation requirement less than 72 h. Shock. 4. Capacity to provide informed consent (patient or patient's direct relative) 5. Availability of convalescent plasma units compatible with ABO blood type of the subject. EXCLUSION CRITERIA: Subjects are not eligible for the trial if they meet any of the following criteria: 1. Contraindication for transfusion (e.g., prior anaphylaxis, congestive heart failure) 2. Hemodynamic instability (PA < 60 mmHg refractory to vasopressors) 3. Uncontrolled concomitant infections\ 4. Stupor or coma 5. Platelets < 50,000/μL or disseminated intravascular coagulation 6. Serum creatinine > 3.5 mg/dL or dialysis requirement 7. Total bilirubin > 6 mg/dL or jaundice of unknown etiology 8. Myocardial infarction or acute coronary syndrome 9. Active or recent (< 7 days) intracranial hemorrhage 10. Pregnancy Donors: The donors have to meet the following criteria: male between 30 and 60 years with a previous diagnosis of severe COVID-19-associated pneumonia within the last 3 months, with resolution of symptoms of at least 28 days. The rationale for including donors with severe disease is to maximize the probability of collecting convalescent plasma units with high titer of neutralizing antibodies, as the technology to measure this specific type of antibodies is not routinely available in Peru. Aliquots of plasma will be stored for future quantification of neutralizing antibodies. INTERVENTION AND COMPARATOR: Convalescent plasma from donors with previous severe COVID-19 is the investigational medical product. The experimental group will receive 1 to 2 units of 200 to 250 ml of convalescent plasma along with local standard treatment. The control group will receive local standard treatment alone. The participants randomized to plasma will have evaluations at 6 h and 24 h to specifically evaluate possible post transfusion events. All the participants will be evaluated at day 3, day 7, and day 30 after enrolment. MAIN OUTCOMES: Safety outcome: Incidence of serious adverse reactions related to convalescent plasma transfusion within 24 h after convalescent plasma administration. Efficacy outcomes: Mortality from any cause during hospitalization at 30 days post randomization. Length of hospitalization at 30 days post randomization or until hospital discharge. Duration of mechanical ventilation at 30 days post randomization or until hospital discharge. Length of hospitalization in an intensive care unit at 30 days post randomization or until hospital discharge. Exploratory: Oxygen requirement evolution at days 3 and 7. Score Sequential Organ Failure Assessment (SOFA) evolution at days 3 and 7. Dynamics of inflammatory marker (lymphocyte, C-reactive protein (CRP), D-dimer, lactate dehydrogenase (LDH)) evolution at days 3 and 7. Proportion of patients progressing to multi-organ failure at 30 days post randomization or until hospital discharge. Proportion of transfusion related adverse reactions at 30 days post randomization or until hospital discharge. RANDOMIZATION: Randomization will be carried out within the electronic case report form (eCRF) in 1:1 ratio (receive plasma/control) in a randomization process established by blocks of size 2, 4, and 6. Allocation to the treatment arm of an individual patient will not be available to the investigators before completion of the whole randomization process. Randomization blocks will be performed with "ralloc", Stata's randomization process v.16.0. Randomization through the eCRF will be available 24 h every day. BLINDING (MASKING): Both the participants and study staff will be aware of the allocated intervention. Blinded statistical analysis will be performed. NUMBERS TO BE RANDOMIZED (SAMPLE SIZE): The sample size was calculated using the Fleiss formula with continuity correction to detect a mortality reduction from 50 to 20% between the two treatment arms with a confidence level of 95% and a power of 80%. Based on this information, a total of 45 patients per arm would be needed. After adjustment for a drop-out rate of 10% after enrolment, a total of 50 patients per arm (100 patients in total) will be enrolled. TRIAL STATUS: Current protocol version: 5.0 dated January 04, 2021. Recruitment started on September 21, 2020, and is expected to finish by the end of March 2021. TRIAL REGISTRATION: Peruvian Register of Clinical Trials (REPEC) ID: PER-016-20, registered on June 27, 2020. Clinicaltrials.gov ID: NCT04497324 , registered on August 4, 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol.
引用
- Soto A, Krapp F, Vargas A, et al. Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial. Trials. 2021. PMID: 34001174. doi:10.1186/s13063-021-05189-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。